New & Emerging Biologic Agents in CRSwNP: Pathophysiology Insights & Patient Selection Criteria

Released On
April 28, 2022

Expires On
April 28, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Otolaryngology, Primary Care, Internal Medicine

Topic(s)
Respiratory, CRSwNP, Nasal Polyps

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Integrity Continuing Education, Inc.

 

This educational activity is supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity has been designed for allergists, immunologists, nurse practitioners, and physician assistants who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Program Overview

Until recently, the only treatment choices for patients with CRSwNP included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their patients with CRSwNP who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy, criteria that should be used when choosing between biologics and surgery, and patient education in regards to treatment with biologics. These topics will be addressed by expert faculty presenters during this initiative.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the pathophysiologic/immunogenic molecular drivers of chronic rhinosinusitis that lead to the inflammatory endotypes and relevant comorbidities frequently observed in patients with CRSwNP
  • Discuss the differences between currently approved and emerging biologic treatment options for CRSwNP using data from clinical trials and other analyses
  • Incorporate an individualized, patient-centric focus based on consensus criteria for patients with CRSwNP when recommending a biologic therapy or endoscopic sinus surgery

Faculty

FACULTY_NAME

Tara F. Carr, MD

Associate Professor of Medicine
Asthma and Airway Disease Research Center
University of Arizona
Tucson, Arizona

FACULTY_NAME

Joseph K. Han, MD, FARS, FAAAAI

Professor of Otolaryngology & Head and Neck Surgery
Chief, Division of Rhinology & Endoscopic Sinus & Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, Virginia


Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians Continuing Education
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Tara F. Carr, MD
  • Advisor/Consultant: AstraZeneca
  • Advisory Board: Genentech, GlaxoSmithKline
  • Contributor/Reviewer: UpToDate
  • Unbranded Disease State Speaker: Novartis, Regeneron
Joseph K. Han, MD, FARS, FAAAAI
  • Consultant: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 28, 2022 through April 28, 2023 participants must:

  1. Read the learning objectives and faculty disclosures
  2. Complete the pretest
  3. Study the educational activity
  4. Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.